Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension

Molecular Therapy

Volumn 20, Issue 8, 2012, Pages 1516-1528

  Morecroft, Ian ^a   White, Katie ^a   Caruso, Paola ^a   Nilsen, Margaret ^a   Loughlin, Lynn ^a   Alba, Raul ^a   Reynolds, Paul N ^b   Danilov, Sergei M ^c,d   Baker, Andrew H ^a   MacLean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; ADENOVIRUS VECTOR; CITALOPRAM; CYCLINE; KETANSERIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9B9; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SEROTONIN; SHORT HAIRPIN RNA; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; COW; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; GENE TARGETING; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY ENDOTHELIUM CELL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; PULMONARY VASCULAR REMODELING; RAT; SELECTIVE ENZYME INHIBITION; SEROTONIN METABOLISM; SEROTONIN RELEASE; SMOOTH MUSCLE FIBER; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; BOVINAE; RATTUS;

EID: 84864533955     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.70     Document Type: Article

References (50)

1. Chin, KM and Rubin, LJ (2008). Pulmonary arterial hypertension. J Am Coll Cardiol 51: 1527-1538.
2. Lane, KB, Machado, RD, Pauciulo, MW, Thomson, JR, Phillips, JA 3rd, Loyd, JE et al.; International PPH Consortium. (2000). Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26: 81-84.
3. Keegan, A, Morecroft, I, Smillie, D, Hicks, MN and MacLean, MR (2001). Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 89: 1231-1239.
4. Guignabert, C, Izikki, M, Tu, LI, Li, Z, Zadigue, P, Barlier-Mur, AM et al. (2006). Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98: 1323-1330.
5. Morecroft, I, Dempsie, Y, Bader, M, Walther, DJ, Kotnik, K, Loughlin, L et al. (2007). Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49: 232-236.
6. Eddahibi, S, Guignabert, C, Barlier-Mur, AM, Dewachter, L, Fadel, E, Dartevelle, P et al. (2006). Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113: 1857-1864.
7. Morecroft, I, Heeley, RP, Prentice, HM, Kirk, A and MacLean, MR (1999). 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 128: 730-734.
8. Morecroft, I, Pang, L, Baranowska, M, Nilsen, M, Loughlin, L, Dempsie, Y et al. (2010). In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res 85: 593-603.
9. Eddahibi, S, Humbert, M, Fadel, E, Raffestin, B, Darmon, M, Capron, F et al. (2001). Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108: 1141-1150.
10. Marcos, E, Fadel, E, Sanchez, O, Humbert, M, Dartevelle, P, Simonneau, G et al. (2004). Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94: 1263-1270.
11. Liu, Y, Li, M, Warburton, RR, Hill, NS and Fanburg, BL (2007). The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J 21: 2725-2734.
12. Walther, DJ, Peter, JU, Bashammakh, S, Htnagl, H, Voits, M, Fink, H et al. (2003). Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299: 76.
13. Sakowski, SA, Geddes, TJ, Thomas, DM, Levi, E, Hatfield, JS and Kuhn, DM (2006). Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res 1085: 11-18.
14. Ni, W, Geddes, TJ, Priestley, JR, Szasz, T, Kuhn, DM and Watts, SW (2008). The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol 154: 663-674.
15. Metzger, R, Franke, FE, Bohle, RM, Alhenc-Gelas, F and Danilov, SM (2011). Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity. Microvasc Res 81: 206-215.
16. Izikki, M, Hanoun, N, Marcos, E, Savale, L, Barlier-Mur, AM, Saurini, F et al. (2007). Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 293: L1045-L1052.
17. Pan, J, Copland, I, Post, M, Yeger, H and Cutz, E (2006). Mechanical stretch-induced serotonin release from pulmonary neuroendocrine cells: implications for lung development. Am J Physiol Lung Cell Mol Physiol 290: L185-L193.
18. Kay, JM, Keane, PM and Suyama, KL (1985). Pulmonary hypertension induced in rats by monocrotaline and chronic hypoxia is reduced by p- chlorophenylalanine. Respiration 47: 48-56.
19. Villal, CM and Centuri, D (2007). Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 376: 45-63.
20. Li, N, Wall, NH, Ladjevardi, M and Hjemdahl, P (1997). Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 8: 517-523.
21. Hickman, AB, Klein, DC and Dyda, F (1999). Melatonin biosynthesis: the structure of serotonin N-acetyltransferase at 2.5 A resolution suggests a catalytic mechanism. Mol Cell 3: 23-32.
22. Yadav, VK, Balaji, S, Suresh, PS, Liu, XS, Lu, X, Li, Z et al. (2010). Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 16: 308-312.
23. Danilov, SM, Gavrilyuk, VD, Franke, FE, Pauls, K, Harshaw, DW, McDonald, TD et al. (2001). Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 280: L1335-L1347.
24. Balyasnikova, IV, Yeomans, DC, McDonald, TB and Danilov, SM (2002). Antibodymediated lung endothelium targeting: in vivo model on primates. Gene Ther 9: 282-290.
25. Reynolds, PN, Zinn, KR, Gavrilyuk, VD, Balyasnikova, IV, Rogers, BE, Buchsbaum, DJ et al. (2000). A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2: 562-578.
26. Miller, WH, Brosnan, MJ, Graham, D, Nicol, CG, Morecroft, I, Channon, KM et al. (2005). Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Mol Ther 12: 321-327.
27. Reynolds, AM, Xia, W, Holmes, MD, Hodge, SJ, Danilov, S, Curiel, DT et al. (2007). Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 292: L1182-L1192.
28. Reynolds, PN, Nicklin, SA, Kaliberova, L, Boatman, BG, Grizzle, WE, Balyasnikova, IV et al. (2001). Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 19: 838-842.
29. Guignabert, C, Raffestin, B, Benferhat, R, Raoul, W, Zadigue, P, Rideau, D et al. (2005). Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111: 2812-2819.
30. Kawut, SM, Horn, EM, Berekashvili, KK, Lederer, DJ, Widlitz, AC, Rosenzweig, EB et al. (2006). Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 19: 370-374.
31. Eddahibi, S, Hanoun, N, Lanfumey, L, Lesch, KP, Raffestin, B, Hamon, M et al. (2000). Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105: 1555-1562.
32. Camilleri, M (2010). LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs 13: 921-928.
33. Jin, H, Cianchetta, G, Devasagayaraj, A, Gu, K, Marinelli, B, Samala, L et al. (2009). Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors. Bioorg Med Chem Lett 19: 5229-5232.
34. Chin, A, Svejda, B, Gustafsson, BI, Granlund, AB, Sandvik, AK, Timberlake, A et al. (2012). The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion. Am J Physiol Gastrointest Liver Physiol 302: G397-G405.
35. Liu, Y, Suzuki, YJ, Day, RM and Fanburg, BL (2004). Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95: 579-586.
36. Liu, Y and Fanburg, BL (2006). Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. Am J Respir Cell Mol Biol 34: 182-191.
37. Izikki, M, Guignabert, C, Fadel, E, Humbert, M, Tu, L, Zadigue, P et al. (2009). Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119: 512-523.
38. Fishman, AP (1976). Hypoxia on the pulmonary circulation. How and where it acts. Circ Res 38: 221-231.
39. Haas, F and Bergofsky, EH (1972). Role of the mast cell in the pulmonary pressor response to hypoxia. J Clin Invest 51: 3154-3162.
40. Humbert, M, Sitbon, O, Chaouat, A, Bertocchi, M, Habib, G, Gressin, V et al. (2010). Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122: 156-163.
41. White, K, Dempsie, Y, Nilsen, M, Wright, AF, Loughlin, L and MacLean, MR (2011). The serotonin transporter, gender, and 17? oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 90: 373-382.
42. Murray, F, MacLean, MR and Pyne, NJ (2003). An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension. Br J Pharmacol 138: 1313-1319.
43. Reynolds, PN (2011). Gene therapy for pulmonary hypertension: prospects and challenges. Expert Opin Biol Ther 11: 133-143.
44. Morrell, NW, Atochina, EN, Morris, KG, Danilov, SM and Stenmark, KR (1995). Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 96: 1823-1833.
45. Orte, C, Polak, JM, Haworth, SG, Yacoub, MH and Morrell, NW (2000). Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 192: 379-384.
46. Balyasnikova, IV, Berestetskaya, JV, Visintine, DJ, Nesterovitch, AB, Adamian, L and Danilov, SM (2010). Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting. Microvasc Res 80: 355-364.
47. Lee, SL, Wang, WW, Moore, BJ and Fanburg, BL (1991). Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ Res 68: 1362-1368.
48. Follenzi, A, Sabatino, G, Lombardo, A, Boccaccio, C and Naldini, L (2002). Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 13: 243-260.
49. Iida, Y, Sawabe, K, Kojima, M, Oguro, K, Nakanishi, N and Hasegawa, H (2002). Proteasome-driven turnover of tryptophan hydroxylase is triggered by phosphorylation in RBL2H3 cells, a serotonin producing mast cell line. Eur J Biochem 269: 4780-4788.
50. Alba, R, Bradshaw, AC, Coughlan, L, Denby, L, McDonald, RA, Waddington, SN et al. (2010). Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116: 2656-2664.